Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A pharmaceutical composition of cerebroprotein hydrolysate and applications thereof

A cerebroprotein hydrolyzate and composition technology, applied in the field of new drug development, can solve the problems of ligustrazine hydrochloride, danshensu sodium, troxerutin and the like that have not been seen and have not been seen, so as to prevent cerebral infarction and improve brain function. Effects of handicap situations

Inactive Publication Date: 2015-09-09
邓学峰
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] At present, there is no study on the use of ligustrazine hydrochloride, danshensu sodium, and troxerutin in the prevention of cerebral infarction for cerebral dysfunction, and there is no research on the use of ligustrazine hydrochloride, danshensu sodium, and troxerutin in combination with cerebral infarction. Related reports on the use of protein hydrolyzate to improve brain dysfunction and prevent cerebral infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Dissolve 50-200 parts of ligustrazine hydrochloride, 1-4 parts of Danshensu sodium, and 100-300 parts of trehalose in water for injection at 40-50°C, which accounts for 40-50% of the total liquid, and stir while adding. After dissolving completely, add 50-70℃ water for injection to 80-90% of the total amount of the drug solution. While stirring, add 15-60 parts of cerebroprotein hydrolysate, 100-400 parts of troxerutin, and bisulfite. Sodium 1-5 parts, after it is completely dissolved, adjust the pH value to 5.5-6.5 with disodium hydrogen phosphate buffer, add water for injection to the full volume, filter through a 0.22μm membrane, and fill it in an ampoule aseptically. Steam sterilized at 121°C for 30 minutes to prepare a small volume injection.

Embodiment 2

[0014] Example 2 Dissolve 100 parts of ligustrazine hydrochloride, 2 parts of Danshensu sodium, and 150 parts of trehalose in water for injection at 40-50°C, which accounts for 40-50% of the total liquid medicine, and stir while adding, until completely dissolved , Add 50~70℃ water for injection to 80~90% of the total amount of the liquid, add 30 parts of cerebroprotein hydrolysate, 200 parts of troxerutin and 2.5 parts of sodium bisulfite one by one while stirring, and wait for complete dissolution Afterwards, adjust the pH to 5.5-6.5 with disodium hydrogen phosphate buffer, add water for injection to the full amount, filter through a 0.22μm membrane, and fill it in an ampoule aseptically, each containing 5ml, steam at 121℃ Sterilize for 30 minutes to prepare a small volume injection of 5ml.

Embodiment 3

[0015] Example 3 Dissolve 200 parts of ligustrazine hydrochloride, 4 parts of Danshensu sodium, and 300 parts of trehalose in water for injection at 40-50°C, which accounts for 40-50% of the total amount of the drug solution, and stir while adding, until it is completely dissolved , Add water for injection at 50~70℃ to 80~90% of the total amount of the liquid, add 60 parts of cerebroprotein hydrolysate, 400 parts of troxerutin, and 5 parts of sodium bisulfite one by one while stirring. Afterwards, adjust the pH to 5.5-6.5 with disodium hydrogen phosphate buffer, add water for injection to the full amount, filter through a 0.22μm membrane, and fill it in an ampoule aseptically, each containing 10ml, steam at 121℃ Sterilize for 30 minutes to prepare 10ml small volume injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A pharmaceutical composition of cerebroprotein hydrolysate and applications thereof are disclosed. The composition comprises 15-60 parts by weight of the cerebroprotein hydrolysate, 50-200 parts by weight of ligustrazine hydrochloride, 1-4 parts by weight of sodium DL-beta-(3,4-dihydroxyphenyl)lactate and 100-400 parts by weight of troxerutin. The ligustrazine hydrochloride, the sodium DL-beta-(3,4-dihydroxyphenyl)lactate, the troxerutin and the cerebroprotein hydrolysate are combined for the first time and blended through a proper ratio. The composition has good effects of improving disordered brain functions and preventing cerebral infarction, and can be prepared into any clinically or pharmaceutically acceptable preparation form, preferentially an injection. The composition is definite in effective components and definite in contents, and is mainly used for preparing medicines improving brain functions. A preparing process is simple, convenient and feasible. A preparation is high and stable in quality. The composition is suitable for large-scale industrial production.

Description

technical field [0001] The invention relates to the technical field of new drug development, in particular to a pharmaceutical composition of cerebroprotein hydrolyzate and its application. Background technique [0002] Brain dysfunction includes brain tissue ischemia and hypoxia injury, acute and chronic cerebrovascular disease, brain trauma, various toxic encephalopathy and other causes of cranial nerve dysfunction and memory loss, congenital brain hypoplasia, children's mental retardation , senile dementia, etc. Brain tissue is very sensitive to ischemia and hypoxia. With the aging trend of society and the prolongation of life expectancy, the incidence of hypoxic-ischemic cerebrovascular disease has increased significantly, seriously endangering human health and bringing heavy burdens to society and families. Cognitive dysfunction caused by cerebral ischemia and reperfusion has also received increasing attention. Dementia is a common senile disease, and it is also a re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/01A61P9/10A61P25/00A61P7/02A61P9/00A61P25/28A61K31/7048A61K31/4965A61K31/192
Inventor 邓学峰耿华靖
Owner 邓学峰
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com